Nasdaq rxrx.

Jul 18, 2023 · After announcing that it would get a $50 million investment from NVIDIA (NVDA 0.27%) on July 12, Recursion Pharmaceuticals (RXRX 8.83%) saw its stock blast off, rising 87% over the following two ... Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors …Aug 11, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (-2.63%) -$0.26 ... When it comes to complex biotech stocks like Recursion Pharmaceuticals (RXRX-2.63%), skilled investors ... Shares of Recursion Pharmaceuticals (RXRX-2.63%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist Add to Portfolio RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS …

Stocks RXRX Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future December 14, 2023 — 02:31 pm EST Written by Sushree Mohanty …

Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The fund owned 2,335,132 shares of the company's stock after selling …

December 15, 2023 at 3:06 AM · 4 min read. In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is the latest addition in Srini Akkaraju and Michael Dybbs’ hedge fund portfolio, as Samsara BioCapital bought 775,583 shares worth $28.31 million ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Jan 19, 2024 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements.

2 days ago · Mirae Asset Global Investments Co. Ltd. increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 31.0% in the 3rd quarter, according to the company in ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is the latest addition in Srini Akkaraju and Michael Dybbs’ hedge fund portfolio, as Samsara BioCapital bought 775,583 shares worth $28.31 million ...Nov 16, 2023 · JuSun/iStock via Getty Images. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline.That's because it has been advancing two ... It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance.Twist Bioscience (NASDAQ: TWST), like RXRX, is a genomics stock positioned to win no matter which companies capture the largest market share.TWST creates synthetic DNA, which is critical to early ...

The firm has a market cap of $2.09 billion, a PE ratio of -6.60 and a beta of 0.63. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report) last announced its earnings results on Thursday ...Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing ...November 10, 2023 at 5:06 AM · 3 min read. With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX) may be sending very bearish signals at the moment, given ...So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company that is involved in decoding biology and screening drugs to arrange them in a way that can aid the efficient ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on January 17, 2024.The analyst firm set a price target for $15.00 expecting RXRX to rise to within ...

Jan 19, 2024 · A. The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Wednesday, January 17, 2024. The analyst firm set a price target for 15.00 expecting RXRX to ... Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Feb 17, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ... December 15, 2023 at 3:06 AM · 4 min read. In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on ...Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ...Nov 10, 2023 · With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) may be sending very bearish signals at the moment, given that almost half of all the Biotechs ... Feb 17, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ... Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share volumes, and more. Make informed investments with Nasdaq.

Jul 13, 2023 · Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months.

Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Aug 11, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (-2.63%) -$0.26 ... When it comes to complex biotech stocks like Recursion Pharmaceuticals (RXRX-2.63%), skilled investors ... Jul 18, 2023 · After announcing that it would get a $50 million investment from NVIDIA (NVDA 0.27%) on July 12, Recursion Pharmaceuticals (RXRX 8.83%) saw its stock blast off, rising 87% over the following two ... Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... SALT LAKE CITY , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16,

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Price, Quote, News & History | Nasdaq Created with Sketch. Market Activity Funds + ETFs P/E & PEG Ratios when trading, helping... Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Instagram:https://instagram. nutri seed crunch banana healthy traditionnanapercent27s handmade embroiderytesa765816 Biotech firm Recursion (NASDAQ:RXRX) said on Wednesday that it had secured a $50M investment from Nvidia , which was implemented as a private investment in public equity. RXRX shares jump +72.7% ...The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ... banana republic tank tops womenzena swiss slim inox peeler super sharp lightweight SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery ...In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings. tiersegnungen RXRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Recursion Pharmaceuticals, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and …SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …